Diabetic Peripheral Neuropathy Market

Market Overview:

The 7 major diabetic peripheral neuropathy markets reached a value of US$ 2,903.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,365.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.74% during 2024-2034.

The diabetic peripheral neuropathy market has been comprehensively analyzed in IMARC's new report titled "Diabetic Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Diabetic peripheral neuropathy refers to a medical condition in which nerve damage occurs as a complication of diabetes. It affects the nerves, mainly in the feet and hands, and can be motor, sensory, or both. The most common indications associated with this illness include a feeling of tingling or numbness in the feet or hands, burning, stabbing, or shooting pain in the affected areas, ulcers, infections, loss of coordination and balance, muscle weakness, particularly in the feet, etc. Over time, the condition can lead to serious complications, such as foot ulcers, infections, and even amputations, if left untreated. The diagnosis of diabetic peripheral neuropathy generally requires a combination of the patient's clinical features, medical history, and a physical exam. An electromyography (EMG), in which a tiny needle is inserted through the skin to measure the electrical activities of the muscle, is also utilized to evaluate nerve function. The healthcare provider may further perform specific investigations, such as filament testing, sensory tests, nerve conduction studies, etc., to confirm the diagnosis and rule out other possible conditions.

The rising cases of uncontrolled high blood sugar levels, which weaken the capillary walls and damage nerves, are primarily driving the diabetic peripheral neuropathy market. Moreover, the increasing incidences of numerous associated risk factors, including excessive alcohol consumption, chronic inflammation, autoimmune disorders, smoking, kidney diseases, etc., are also augmenting the market growth. Apart from this, the widespread adoption of effective drugs, like anti-seizures and tricyclic antidepressants, to ease nerve pain as well as improve the quality of life in patients is creating a positive outlook for the market. Furthermore, the emerging popularity of pharmacotherapy coupled with certain lifestyle modifications, such as smoking cessation, regular exercises, consumption of a healthy or balanced diet, etc., is also bolstering the market growth. Additionally, various key players are making extensive investments in research initiatives to develop novel, cost-effective topical therapies for treating the ailment. This, in turn, is acting as another significant growth-inducing factor. Moreover, the inflating usage of transcutaneous electrical nerve stimulation therapy, which aims to alleviate symptomatic pain by stimulating sensory nerves, is expected to drive the diabetic peripheral neuropathy market during the forecast period. 

IMARC Group's new report provides an exhaustive analysis of the diabetic peripheral neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for diabetic peripheral neuropathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the diabetic peripheral neuropathy market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the diabetic peripheral neuropathy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the diabetic peripheral neuropathy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current diabetic peripheral neuropathy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the diabetic peripheral neuropathy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the diabetic peripheral neuropathy market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the diabetic peripheral neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of diabetic peripheral neuropathy across the seven major markets?
• What is the number of prevalent cases (2018-2034) of diabetic peripheral neuropathy by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of diabetic peripheral neuropathy by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with diabetic peripheral neuropathy across the seven major markets?
• What is the size of the diabetic peripheral neuropathy patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of diabetic peripheral neuropathy?
• What will be the growth rate of patients across the seven major markets?
   

Diabetic Peripheral Neuropathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for diabetic peripheral neuropathy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the diabetic peripheral neuropathy market?
• What are the key regulatory events related to the diabetic peripheral neuropathy market?
• What is the structure of clinical trial landscape by status related to the diabetic peripheral neuropathy market?
• What is the structure of clinical trial landscape by phase related to the diabetic peripheral neuropathy market?
• What is the structure of clinical trial landscape by route of administration related to the diabetic peripheral neuropathy market?